Schedule 13D ownership disclosure

CRISPR Therapeutics AG

Security class unavailable · CUSIP: H17182108

Event date: 2018-01-05

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
Unavailable
Percent of class
4.0000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000905718-18-000056
Form type
SC 13D/A
Filer
Abingworth LLP
CIK
CIK 1397144
Filed
Jan 16, 2018
Reporting period
Jan 05, 2018
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub